Anti-Keratin14 [LL002]
Invented by Prof Birgit Lane from A*STAR Accelerate Technologies Pte Ltd
Invented at Queen Mary University of London
- Datasheet
- References (11)
- Inventor Info
Info
| Catalogue Number | 151441 |
| Applications | FACS IHC IF WB |
| Antigen/Gene or Protein Targets | Keratin 14 |
| Reactivity | Human, Mouse and Pig |
| Relevance |
Monoclonal antibody directed keratin 14, with use in identifying squamous cell carcinoma, and distinguishing basal breast carcinomas. Background and Research Application Keratin 14, a type 1 intermediate filament protein, is one of the two keratins alongside keratin 5 which distinguish stratifying epithelial cell types from simple epithelial cell types. LL002 antibody therefore characterises stratifying/keratinocyte cell types. This is useful for the identification of squamous cell carcinomas, and as a prognostic marker in breast carcinoma. LL002 labels the basal layer of stratifying squamous and non-squamous epithelia, with a cytoplasmic staining pattern. This can help distinguish between basal and non-basal subtypes of breast carcinomas. |
| Host | Mouse |
| Immunogen | The last 16 carboxy-terminal amino acids of human keratin, in the form of a synthetic peptide. This was coupled to thyroglobulin by the extra Cys added at the N terminus. |
| Immunogen UniProt ID | P02533 |
| Subclass | IgG3 |
| Molecular Weight (kDa) | 50 |
| Myeloma Used | Sp2/0-Ag14 |
| Recommended Growing Conditions | DMEM + 5% FCS |
| Strain | Balb/c |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest Anti-keratin14 did not stain the transitional epithelium including the prostatic part of the urethra. This antibody has also proved a good marker for differentiation of intraductal from invasive salivary duct carcinoma by the positive staining of basal cells surrounding the in-situ neoplasm alongside differentiation of benign prostate from prostate carcinoma. Concentration 1mg/ml as standard |
| Research Area | Cell Signaling & Signal Transduction |
References: 11 entries
Hagiyama et al. 2017. Front Physiol. 8:997. PMID: 29259558.
Kuga et al. 2016. Sci Rep. 6:26557. PMID: 27222304.
Haikala et al. 2016. Cell Cycle. 15(3):316-23. PMID: 26873145.
Bohn et al. 2010. Int J Clin Exp Pathol. 3(6):600-7. PMID: 20661408.
p16INK4a expression in basal-like breast carcinoma.
Europe PMC ID: 20661408
Kurzrock et al. 2008. Am J Physiol Renal Physiol. 294(6):F1415-21. PMID: 18367656.
Label-retaining cells of the bladder: candidate urothelial stem cells.
Europe PMC ID: 18367656
Purkis et al. 1990. J Cell Sci. 97 ( Pt 1):39-50. PMID: 1701769.
Antibody markers of basal cells in complex epithelia.
Europe PMC ID: 1701769
Schaafsma et al. 1990. Am J Pathol. 136(2):329-43. PMID: 1689541.
Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression.
Europe PMC ID: 1689541
Add a reference
References: 11 entries
Hagiyama et al. 2017. Front Physiol. 8:997. PMID: 29259558.
Kuga et al. 2016. Sci Rep. 6:26557. PMID: 27222304.
Haikala et al. 2016. Cell Cycle. 15(3):316-23. PMID: 26873145.
Bohn et al. 2010. Int J Clin Exp Pathol. 3(6):600-7. PMID: 20661408.
p16INK4a expression in basal-like breast carcinoma.
Kurzrock et al. 2008. Am J Physiol Renal Physiol. 294(6):F1415-21. PMID: 18367656.
Label-retaining cells of the bladder: candidate urothelial stem cells.
Purkis et al. 1990. J Cell Sci. 97 ( Pt 1):39-50. PMID: 1701769.
Antibody markers of basal cells in complex epithelia.
Schaafsma et al. 1990. Am J Pathol. 136(2):329-43. PMID: 1689541.
Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression.
Add a reference
